Investor Relations

SEC Filings

Document Highlights
Other Filings
Filing Description Filing Type Filing Date Event Date Download
Prospectus 424B7 3/29/2017
8-K 8-K 3/27/2017 3/27/2017
Abstract: Registrant filed the unaudited pro forma condensed combined statement of operations of the registrant and Valence Health Inc., excluding Cicerone Health Solutions Inc., for the year ended Dec. 31, 2016.
Prospectus 424B3 3/27/2017
Prospectus 424B7 3/27/2017
10-K 10-K 3/3/2017 12/31/2016
8-K 8-K 2/28/2017 2/28/2017
Abstract: On Feb. 28, registrant reported its financial results for the quarter and for the year ended Dec. 31, 2016.
8-K 8-K 2/8/2017 2/8/2017
Abstract: On Feb. 8, registrant reported the schedule of its 2017 annual meeting of shareholders.
8-K 8-K/A 12/19/2016 12/19/2016
Abstract: Registrant filed an amendment to the Form 8-K filed Oct. 3 to filed exhibit 23.1.
8-K 8-K 12/5/2016 12/5/2016
Abstract: Registrant reported that on Nov. 29, it and Evolent Health LLC entered into a purchase agreement JP Morgan Securities LLC and Goldman Sachs & Co. issue and sell $110.0 million aggregate principal amount of its 2.00% convertible senior notes due 2021. The indenture, among other things, was included by exhibit.
8-K 8-K 11/30/2016 11/29/2016
Abstract: On Nov. 29, registrant announced the pricing of $110 million of 2.00% convertible senior notes due 2021.
8-K 8-K 11/29/2016 11/29/2016
Abstract: On Nov. 29, registrant announced that it intends to offer $110 million of convertible senior notes due 2021.
10-Q 10-Q 11/10/2016 9/30/2016
8-K 8-K 11/9/2016 11/9/2016
Abstract: On Nov. 9, registrant reported its net loss for the quarter ended Sept.
8-K 8-K 10/3/2016 10/3/2016
Abstract: On Oct. 3, registrant announced the completion of its acquisition of Valence Health Inc. The first amendment to agreement and plan of merger was included by exhibit.
8-K 8-K 9/22/2016 9/22/2016
Abstract: Registrant reported that on Sept. 22, the sale of the shares of the registrant’s class A common stock by the Advisory Board Co., among others, pursuant to the overallotment option closed. The opinion and consent of Cravath Swaine & Moore LLP were included by exhibit.
8-K 8-K 9/14/2016 9/14/2016
Abstract: Registrant reported that on Sept. 8, it and Evolent Health LLC entered into an underwriting agreement for the sale of 7.5 million shares of class A common stock of the registrant. The underwriting agreement and the opinion and consent of Cravath Swaine & Moore LLP were included by exhibit.
Prospectus 424B7 9/9/2016
Prospectus 424B7 9/6/2016
10-Q 10-Q 8/9/2016 6/30/2016
8-K 8-K 8/4/2016 8/4/2016
Abstract: On Aug. 4, registrant reported its net loss for the quarter ended June 30.

Displaying 1 to 20 (of 55 filings)
  • 1